Apellis Pharmaceuticals (APLS) Enterprise Value (2020 - 2025)
Historic Enterprise Value for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to -$480.6 million.
- Apellis Pharmaceuticals' Enterprise Value fell 2068.94% to -$480.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$480.6 million, marking a year-over-year decrease of 2068.94%. This contributed to the annual value of -$412.6 million for FY2024, which is 1711.98% down from last year.
- Per Apellis Pharmaceuticals' latest filing, its Enterprise Value stood at -$480.6 million for Q3 2025, which was down 2068.94% from -$371.5 million recorded in Q2 2025.
- Apellis Pharmaceuticals' Enterprise Value's 5-year high stood at -$327.0 million during Q1 2024, with a 5-year trough of -$965.3 million in Q1 2022.
- Moreover, its 5-year median value for Enterprise Value was -$480.6 million (2025), whereas its average is -$549.2 million.
- As far as peak fluctuations go, Apellis Pharmaceuticals' Enterprise Value crashed by 6466.07% in 2022, and later skyrocketed by 5732.73% in 2024.
- Over the past 5 years, Apellis Pharmaceuticals' Enterprise Value (Quarter) stood at -$700.6 million in 2021, then increased by 21.05% to -$553.1 million in 2022, then soared by 36.3% to -$352.3 million in 2023, then dropped by 17.12% to -$412.6 million in 2024, then decreased by 16.48% to -$480.6 million in 2025.
- Its Enterprise Value stands at -$480.6 million for Q3 2025, versus -$371.5 million for Q2 2025 and -$359.8 million for Q1 2025.